Fulcrum Therapeutics Inc
NASDAQ:FULC

Watchlist Manager
Fulcrum Therapeutics Inc Logo
Fulcrum Therapeutics Inc
NASDAQ:FULC
Watchlist
Price: 11.31 USD -0.26% Market Closed
Market Cap: 612.1m USD

Relative Value

There is not enough data to reliably calculate the relative value of FULC.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

FULC Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
49
Median 3Y
28.2
Median 5Y
30.4
Industry
2.7
vs History
vs Industry
Median 3Y
-6.3
Median 5Y
-5.3
Industry
21.5
Forward
-9.4
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-5.7
Industry
16.7
vs History
vs Industry
Median 3Y
-5.4
Median 5Y
-5.6
Industry
23
vs History
16
vs Industry
68
Median 3Y
1.6
Median 5Y
1.9
Industry
2.3
vs History
vs Industry
3
Median 3Y
0.1
Median 5Y
11
Industry
2.9
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.6
vs History
vs Industry
49
Median 3Y
-1.2
Median 5Y
-2.2
Industry
13.2
Forward
-4.9
vs History
vs Industry
48
Median 3Y
-1.2
Median 5Y
-2.2
Industry
16.6
Forward
-4.8
vs History
vs Industry
14
Median 3Y
-1.8
Median 5Y
-2.6
Industry
15.8
vs History
vs Industry
18
Median 3Y
-1.8
Median 5Y
-2.5
Industry
19
vs History
8
vs Industry
6
Median 3Y
6.2
Median 5Y
12
Industry
2

Multiples Across Competitors

FULC Competitors Multiples
Fulcrum Therapeutics Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
612m USD 0 -11.4 -6.9 -6.7
US
Eli Lilly and Co
NYSE:LLY
1T USD 17.1 55.2 37 39.7
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
498B USD 5.4 19.8 16.2 21
CH
Roche Holding AG
SIX:ROG
261.4B CHF 4.2 27.7 11.8 13.8
UK
AstraZeneca PLC
LSE:AZN
213.8B GBP 5 30.7 108.6 158.9
CH
Novartis AG
SIX:NOVN
210.3B CHF 4.7 18.4 11.7 15.1
US
Merck & Co Inc
NYSE:MRK
261.8B USD 4.1 13.8 9.8 11.6
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.6 13.9 9.7 11.3
IE
Endo International PLC
LSE:0Y5F
212.8B USD 91.8 -72.8 337 845
US
Pfizer Inc
NYSE:PFE
141.6B USD 2.3 14.4 7.4 10.1
P/E Multiple
Earnings Growth PEG
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
Average P/E: 24.2
Negative Multiple: -11.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
55.2
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.8
29%
0.7
CH
Roche Holding AG
SIX:ROG
27.7
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.7
37%
0.8
CH
Novartis AG
SIX:NOVN
18.4
17%
1.1
US
Merck & Co Inc
NYSE:MRK
13.8
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.9
3%
4.6
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -72.8 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.4
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
Average EV/EBITDA: 439.5
Negative Multiple: -6.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.2
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.8
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.6
10%
10.9
CH
Novartis AG
SIX:NOVN
11.7
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.8
6%
1.6
DK
Novo Nordisk A/S
CSE:NOVO B
9.7
1%
9.7
IE
E
Endo International PLC
LSE:0Y5F
337
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.4
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
Fulcrum Therapeutics Inc
NASDAQ:FULC
Average EV/EBIT: 1 882.9
Negative Multiple: -6.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.7
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
21
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.8
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
158.9
23%
6.9
CH
Novartis AG
SIX:NOVN
15.1
12%
1.3
US
Merck & Co Inc
NYSE:MRK
11.6
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
11.3
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
845
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
7%
1.4